<- Go Home
Aptinyx Inc.
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Market Cap
$6.5M
Volume
1.1M
Cash and Equivalents
$44.6M
EBITDA
-$53.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$35.7M
Profit Margin
N/A
52 Week High
$0.72
52 Week Low
$0.01
Dividend
N/A
Price / Book Value
0.36
Price / Earnings
-0.10
Price / Tangible Book Value
0.36
Enterprise Value
-$10.9M
Enterprise Value / EBITDA
0.20
Operating Income
-$53.9M
Return on Equity
138.06%
Return on Assets
-43.58
Cash and Short Term Investments
$44.6M
Debt
$27.2M
Equity
$18.3M
Revenue
N/A
Unlevered FCF
-$25.7M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium